Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Theravance Biopharma (TBPH) Asset Writedowns and Impairment (2016 - 2024)

Theravance Biopharma (TBPH) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with -$13000.0 as the latest value for Q4 2024.

Quarterly Asset Writedowns and Impairment changed N/A to -$13000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2024, changed N/A year-over-year, with the annual reading at $4.5 million for FY2024, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2024 was -$13000.0 at Theravance Biopharma, down from $1.6 million in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $1.6 million in Q3 2024, with the low at -$13000.0 in Q4 2024.